ASH 2014 | ASH 2014: Phase II SPRINT study of lenalidomide in relapsed/refractory mantle cell lymphoma
Marek Trněný
Prof Marek Trněný (Charles University Hospital, Prague, Czech Republic) at the 2014 American Society of Hematology (ASH) Annual Meeting discusses the phase 2 SPRINT (MCL-002) study of lenalidomide versus investigator’s choice in relapsed or refractory mantle cell lymphoma, including the study design, efficacy and safety endpoints, and conclusions
Related videos
2:08
MABCUTE: rituximab maintenance in R/R indolent NHL
Simon Rule
1:38
The UK treatment landscape of mantle cell lymphoma
Simon Rule
3:05
Allo-SCT upfront for MCL: feasible for a small subgroup?
Simon Rule
2:15
Defining the group of MCL patients who do well without treatment
Simon Rule
2:01
Ublituximab, umbralisib and ibrutinib in CLL and NHL
Loretta Nastoupil
